Ladenburg Thalmann Downgrades Acrivon Therapeutics to Neutral

Acrivon Therapeutics, Inc. -3.15% Post

Acrivon Therapeutics, Inc.

ACRV

7.69

7.69

-3.15%

0.00% Post

Ladenburg Thalmann analyst Aydin Huseynov downgrades Acrivon Therapeutics (NASDAQ: ACRV) from Buy to Neutral.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via